Skip to main content
Caplight Logo









Nirmidas Biotech

Nirmidas Biotech

Private
Mountain View, CaliforniaHealthcare & Life Scienceshttps://nirmidas.com

Last Round

Grant

Mar 27, 2017

Total Funding Raised

$4.49M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Nirmidas Biotech is a biotechnology company that develops and commercializes advanced diagnostic and imaging products, including test kits, fluorescent probes, and in vivo imaging systems for life science research and clinical applications.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical Devices, Biotech Equipment, Medical Imaging

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting, Data as a Service

AI Layer

Non-AI

Keywords

point-of-care diagnosticsPOC diagnosticsimmunoassayfluorescence imagingbiomarker detectiondiagnostic reagentsmedical imagingfluorescent nanoparticlesclinical laboratory equipmentconfocal scannerin vivo imaginglab-on-a-chiprapid testingdiagnostic consumables

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Nirmidas Biotech Comparables

Compare Nirmidas Biotech with similar companies based on industry and business-model similarity.

Nirmidas Biotech comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
LightDeck Diagnostics
80%
Micropoint Biotechnologies
78%
Achira Labs Private Limited
78%

Nirmidas Biotech Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantMar 27, 2017
SeedAug 18, 2014

Nirmidas Biotech Investors

Notable investors and investment history

Nirmidas Biotech investors
InvestorRounds
NIH RADxGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 20, 2026

    Monthly visitors increased 52% MoM.

  • Nov 8, 2025

    Monthly visitors grew 83% MoM, reaching 1.1K.

Nirmidas Biotech Filings

Explore SEC and related filing metadata, where available.

Nirmidas Biotech filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Nirmidas Biotech's valuation, stock price, and market status.

Is Nirmidas Biotech a public or private company?

Nirmidas Biotech is a private company.

What is the current stock price of Nirmidas Biotech?

Nirmidas Biotech is a private company with no public stock price. No recent secondary market data is available.

How much is Nirmidas Biotech worth (valuation)?

Valuation information for Nirmidas Biotech is not publicly available.

Can I buy Nirmidas Biotech stock?

Nirmidas Biotech shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Nirmidas Biotech's last funding round?

Nirmidas Biotech's most recent funding round was Grant on March 27, 2017.

Who are the main investors in Nirmidas Biotech?

Key investors in Nirmidas Biotech include NIH RADx.

Will Nirmidas Biotech IPO soon?

No public IPO plans have been announced for Nirmidas Biotech.

How can I track Nirmidas Biotech secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Nirmidas Biotech's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersMountain View, California
Employee Range3
Year Founded2013
Last FundingMar 27, 2017

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?